206
Participants
Start Date
January 26, 2021
Primary Completion Date
April 14, 2026
Study Completion Date
July 10, 2026
retifanlimab
INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
epacadostat
epacadostat will be administered orally BID.
pemigatinib
pemigatinib will be administered orally QD.
INCAGN02385
INCAGN2385 will be administered every 2 weeks
INCAGN02390
INCAGN2390 will be administered every 2 weeks
Laura & Isaac Perlmutter Cancer Ctr, New York
Alexandra General Hospital of Athens, Athens
University Hospital of West Attica - Attikon, Athens
Charite - Campus Virchow-Klinikum, Berlin
Hygeia Hospital, Marousi
Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele, Milan
Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano, Milan
European Institute of Oncology, Milan
Cario - Centre Armoricain de Radiotherapie Imagerie Medicale Et Oncologie, Plérin
Virginia Commonwealth University, Richmond
Chu Besancon Hospital Jean Minjoz, Besançon
University of North Carolina At Chapel Hill, Chapel Hill
Georgia Cancer Center, Augusta
Ospedale Santa Maria Ca Foncello, Treviso
Advent Health Medical Group-Orlando 2501, Orlando
Institut Bergonie, Bordeaux
Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach
Miami Cancer Institute, Miami
Broward Health Medical Center, Fort Lauderdale
Klinikum Kassel Gmbh, Kassel
Iov - Istituto Oncologico Veneto Irccs, Padua
Tennessee Oncology, Nashville
Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola - Malpighi, Bologna
The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard
Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau, Saint-Herblain
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola
Barbara Ann Karmanos Cancer Hospital, Detroit
Euromedica General Clinic of Thessaloniki, Thessaloniki
Minnesota Oncology-Maplewood, Coon Rapids
Texas Oncology-Tyler, Sioux Falls
Billings Clinic Cancer Center, Billings
Washington University, St Louis
Midwest Cancer Care, Kansas City
Presidio Ospedaliero Di Summa Antonio Perrino, Brindisi
Hospital Cochin Cancerologie, Paris
Texas Oncology the Woodlands, Shenandoah
Texas Oncology San Antonio, San Antonio
Texas Oncology-Austin Center, Austin
Istituto Nazionale Tumori Irccs Fondazione Pascale, Napoli
Honorhealth, Phoenix
Arizona Oncology Associates, Tucson
New Mexico Cancer Care Alliance, Albuquerque
Comprehensive Cancer Centers of Nevada, Henderson
Universitarsfrauenklinik Ulm, Ulm
UCLA Medical Hematology & Oncology, Los Angeles
Olive View Med Ctr, Sylmar
Institut Gustave Roussy, Villejuif
Alaska Womens Cancer Care Akwcc, Anchorage
H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa
Willamette Valley Cancer Institute, Eugene
Texas Oncology-Fort Worth South Henderson, Fort Worth
O.L.V Ziekenhuis, Aalst
Institut Jules Bordet, Brussels
Ghent University Hospital, Ghent
Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven
Centre Hospitalier Universitaire de Liege - Sart Tilman, Liège
Chu Ucl Namur de Saint Elisabeth, Namur
High Technology Hospital Medcenter, Batumi
Jsc Evex Hospitals, Kutaisi
Todua Clinic, Llc, Tbilisi
Caucasus Medical Centre Llc, Tbilisi
INNOVA, Tbilisi
Multiprofile Clinic Consilium Medulla Llc, Tbilisi
University Clinic Carl Gustav Carus Technical University Dresden, Dresden
Fondazione Policlinico Universitario Agostino Gemelli Irccs, Roma
Lead Sponsor
GOG Foundation
NETWORK
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
Incyte Corporation
INDUSTRY